相关实验视频
Updated: Sep 20, 2025

06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
1.1K
低剂量与高剂量的血栓性并发症 儿童心血管外科手术中大规模出血的四因子原血复合度
Laura Palacio-Guzmán1,2,3, Sergio Alzate-Ricaurte3, Natalia Plata-Ayala1,2,3
1Anesthesiology Department, Fundación Valle del Lili, Cali, Colombia.
Paediatric anaesthesia
|May 28, 2025
概括
四因子前激素复合物缩剂 (4F-PCC) 在小儿心血管外科手术中有效管理严重出血,而不会增加血栓形成风险. 这项研究发现,高剂量和低剂量4F-PCC管理之间的血栓性并发症没有显著差异.
科学领域:
- 心脏病学 心脏病学
- 血液学 血液学 血液学
- 儿科手术 儿科手术
背景情况:
- 儿童心血管外科手术,特别是新生儿和患有先天性心脏缺陷 (CHD) 的婴儿,面临着严重的危及生命的出血风险.
- 心肺绕道 (CPB) 可以通过耗尽凝血因子和血小板来加剧出血.
- 四因子前激素复合物缩剂 (4F-PCC) 提供有针对性的血液静止,但可能会带来血栓形成的风险.
研究的目的:
- 评估四因子前激素复合物缩剂 (4F-PCC) 在儿科心血管手术期间管理严重出血的安全性和有效性.
- 为了在儿科患者中比较低剂量和高剂量4F-PCC管理之间的血栓并发症率.
主要方法:
- 一项回顾性队列研究分析了在2018年1月至2024年4月期间接受心血管手术后4F-PCC的104名儿科患者.
- 患者被分为低剂量 (<35U/kg) 和高剂量 (≥35U/kg) 的4F-PCC组.
- 血栓性并发症的评估是在服用后15天内进行的.
主要成果:
- 总体血栓并发症发生在6.73%的患者中,低于儿科心血管外科手术中11%的全因血栓并发症率.
- 在高剂量 (5.26%) 和低剂量 (8.51%) 组之间没有观察到血栓并发症的显著差异 (p=0.698).
- 高剂量的4F-PCC与更短的CPB时间,但更高的再干预率有关.
结论:
- 四因子前激素复合物缩剂 (4F-PCC) 似乎是儿童心血管外科手术中治疗严重出血的安全和可行的选择.
- 该研究没有发现4F-PCC的更高剂量增加了血栓形成风险的证据.
- 需要进一步的研究来优化4F-PCC的剂量,并探索其在这个患者群体中的预防性应用.
相关概念视频
Venous Thrombosis III: Interprofessional Care
28
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
28
Anticoagulant Drugs: Low-Molecular-Weight Heparins
932
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
932
Disorders of Hemostasis
1.2K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.2K
Venous Thrombosis IV: Nursing Management
27
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
27
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
48
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
48
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K

